Fact Check: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.

Fact Check: "Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million."

What We Know

Anne Wojcicki, co-founder and former CEO of 23andMe, has successfully regained control of the company through her nonprofit, TTAM Research Institute. This acquisition comes after 23andMe filed for Chapter 11 bankruptcy protection earlier in 2025. Initially, Regeneron Pharmaceuticals had announced a bid of $256 million to acquire the company's assets, but Wojcicki's TTAM submitted a higher bid of $305 million, which ultimately won the auction (Reuters, CNBC). The acquisition includes substantial assets of 23andMe, such as its Personal Genome Service and telehealth subsidiary, Lemonaid Health (GenomeWeb).

Analysis

The claim that Anne Wojcicki regained control of 23andMe through her nonprofit's successful bid is supported by multiple reliable sources. The acquisition was confirmed by major news outlets, including Reuters and CNBC, which reported on the details of the bidding process and the final agreement. The fact that TTAM's bid was higher than Regeneron's and that it was accepted indicates a competitive bidding environment, which is typical in bankruptcy auctions.

Moreover, the information provided by these sources is corroborated by official statements from 23andMe and the TTAM Research Institute, which outline the terms of the acquisition and the intentions behind it. Wojcicki expressed her commitment to continuing the mission of 23andMe, emphasizing customer privacy and data management (TechCrunch).

The sources used in this analysis are credible, as they come from established news organizations and official company announcements. However, it is important to note that while Wojcicki's nonprofit is acquiring the company, the deal is still subject to approval by the U.S. Bankruptcy Court (GenomeWeb).

Conclusion

Verdict: True
The claim that Anne Wojcicki regained control of 23andMe after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million is accurate. The evidence from multiple reputable sources confirms that TTAM's bid was successful and that Wojcicki is set to lead the company once again, pending court approval.

Fact Check: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.